Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/87779
Citations
Scopus Web of Science® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorDuffy, D.en
dc.contributor.authorAntill, Y.en
dc.contributor.authorStewart, C.en
dc.contributor.authorYoung, J.en
dc.contributor.authorSpurdle, A.en
dc.date.issued2011en
dc.identifier.citationTwin Research and Human Genetics, 2011; 14(2):111-118en
dc.identifier.issn1832-4274en
dc.identifier.issn1839-2628en
dc.identifier.urihttp://hdl.handle.net/2440/87779-
dc.description.abstractThere is evidence that tamoxifen treatment of BRCA1 and BRCA2 carriers for prior breast cancer increases risk of endometrioid subtype endometrial cancer (EC), and suggestive evidence that BRCA1 and BRCA2 mutation carriers may be predisposed to EC in the absence of tamoxifen exposure. We assessed the association of EC with BRCA1 or BRCA2 mutation status in Australasian breast-ovarian families. Report of at least one case of EC was significantly greater in BRCA1-positive families (35/218 (16%); p = .03) and non-significantly greater in BRCA2-positive families (23/189 (12%); p = .6), compared to high-risk breast cancer families without a BRCA1/2 mutation (86/796 (11%)). EC was the first/concurrent cancer for 41% of EC cases with multiple cancer diagnoses from BRCA1/2 families, and early onset for most of these diagnoses. Mutation status was imputed for ungeno-typed individuals from 57 BRCA1/2 pedigrees reporting EC using BRCAPRO. Effects of genotype on EC diagnosis age, and interaction with tamoxifen therapy, were assessed using Cox proportional hazards regression analysis. EC risk was non-significantly marginally greater for BRCA1 carriers (hazard ratio = 1.25, 95%CI = 0.65-2.41), and BRCA2 carriers (HR = 1.12, 95%CI = 0.51-2.45), compared to non-carrier family members. Tamoxifen therapy was highly significantly associated with EC (HR = 6.68, 95%CI = 3.12-15.15; p = 1.7 x 10(-6)) in BRCA1/2 families, with no evidence for interaction between tamoxifen therapy and BRCA1/2 genotype. Our family-based study supports a 7-fold increase in EC risk with tamoxifen exposure for female family members from BRCA1/2 families. Early onset EC in carriers without tamoxifen use suggests that further study is required to assess association of modest EC risk with BRCA1/2 mutation status alone.en
dc.description.statementofresponsibilityDavid L. Duffy, Yoland C. Antill, Colin J. Stewart, Joanne P. Young, kConFab, and Amanda B. Spurdleen
dc.language.isoenen
dc.publisherCambridge University Press (CUP)en
dc.rights© Cambridge University Press 2011en
dc.subjectBRCA1; BRCA2; endometrial cancer; tamoxifenen
dc.titleReport of endometrial cancer in Australian BRCA1 and BRCA2 mutation-positive familiesen
dc.typeJournal articleen
dc.identifier.rmid0030012030en
dc.identifier.doi10.1375/twin.14.2.111en
dc.relation.granthttp://purl.org/au-research/grants/nhmrc/145684en
dc.relation.granthttp://purl.org/au-research/grants/nhmrc/288704en
dc.relation.granthttp://purl.org/au-research/grants/nhmrc/454508en
dc.identifier.pubid143944-
pubs.library.collectionMedicine publicationsen
pubs.library.teamDS04en
pubs.verification-statusVerifieden
pubs.publication-statusPublisheden
dc.identifier.orcidYoung, J. [0000-0002-1514-1522]en
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.